BeStock  
Stocks › Biotechnology › ROIV

Roivant Sciences ROIV

US equityMarket cap rank #706Biotechnology
$38.66 −$0.31 (-0.78%)
Market closed · Nov 22, 5:30 am ET · Last extended-hours $38.68 +0.06%
Open$38.86
Prev close$38.96
Day range$38.46 – $39.51
Volume3.97M
Market cap$28.01B
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership81.0%-0.85 pts vs. prior quarter
Institutions holding617-3 vs. prior quarter
Insider trades (recent)16 buys / 34 sellsNet selling
Short interest6.30% of floatDays to cover 6.1 · as of 30 Oct 2026
Short-sale volume share23.5%5-day average of daily volume

Short-sale volume as % of daily volume

11%19%27%35%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$132.50M (5 inflow days, 15 outflow days).

Net flow by order size, last 20 sessions

−$113.5MSuper−$19.0MBig+$3.2MMid+$29.4MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 42.3% of shares outstanding.

Largest holders

  • Dan Oren13.55%
  • FMR11.77%
  • BlackRock8.54%
  • Morgan Stanley Investment Management Inc.4.76%
  • Vanguard Capital Management, LLC3.66%
  • Vivek Ramaswamy3.52%
  • State Street Global Advisors3.09%
  • Farallon Capital Management, L.L.C.3.00%

By investor type

  • Mutual Fund55.23%
  • Individual/Insider20.50%
  • Hedge Fund17.33%
  • Public Company2.44%
  • VC/PE Fund2.01%
  • Private Company1.99%
  • Government Pension Fund0.80%
  • Sovereign Wealth Fund0.69%

Reported short interest has risen from 4.24% to 6.30% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Frank Torti Individual/Insider 2026/Q4 +11,996,640 1.7%
BlackRock Mutual Fund 2026/Q4 +13,643,141 8.5%
Jennison Associates LLC Mutual Fund 2026/Q4 +7,585,461 1.7%
Farallon Capital Management, L.L.C. Hedge Fund 2026/Q4 +7,436,533 3.0%
J.P. Morgan Asset Management, Inc. Mutual Fund 2026/Q4 +6,038,676 0.9%
State Street Global Advisors Mutual Fund 2026/Q4 +4,603,612 3.1%
FMR Mutual Fund 2026/Q4 +4,479,045 11.8%
Nearwater Capital Markets, Limited Private Company 2026/Q4 +4,100,000 0.8%
Bank of America Corporation Public Company 2026/Q4 +3,041,189 0.9%
Lord, Abbett & Co. LLC Mutual Fund 2026/Q4 +1,657,032 0.3%
Vanguard Capital Management, LLC Mutual Fund 2026/Q4 +1,508,914 3.7%
Rubric Capital Management LP Hedge Fund 2026/Q4 +1,481,524 1.0%
Invesco Capital Management LLC Mutual Fund 2026/Q4 +1,437,196 1.2%
Janus Henderson Group plc Mutual Fund 2026/Q4 +1,285,041 0.6%
Rockefeller & Co. LLC Mutual Fund 2026/Q4 +1,166,663 0.2%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
11 Nov 2026 Frank Torti President & Vant Chair Sale to Issuer -12,800 $41.85 12,306,950
11 Nov 2026 Mayukh Sukhatme President, Chief Investment Officer & Director Sale to Issuer -1,737 $41.85 386,602
11 Nov 2026 Matthew Gline Chief Executive Officer Sale to Issuer -1,600 $41.85 426,077
11 Nov 2026 Frank Torti President & Vant Chair Other Disposition -1,176,143 $42.01 12,306,950
11 Nov 2026 Mayukh Sukhatme President, Chief Investment Officer & Director Other Disposition -165,444 $42.01 386,602
11 Nov 2026 Matthew Gline Chief Executive Officer Other Disposition -156,307 $42.01 426,077
10 Nov 2026 Richard Pulik Chief Financial Officer Open Market Disposition -47,635 $41.89 38,882
10 Nov 2026 Richard Pulik Chief Financial Officer Derivative Exercise and Sale -252,365 $42.03 38,882
9 Nov 2026 Frank Torti President & Vant Chair Intent to Sell (Form 144) -1,234,964 $41.08 –
9 Nov 2026 Mayukh Sukhatme President, Chief Investment Officer & Director Intent to Sell (Form 144) -173,725 $41.00 –
9 Nov 2026 Matthew Gline Chief Executive Officer Intent to Sell (Form 144) -164,136 $41.00 –
9 Nov 2026 Richard Pulik Chief Financial Officer Intent to Sell (Form 144) -125,000 $41.20 –
9 Nov 2026 Eric Venker President & CEO of Immunovant Open Market Disposition -187,943 $41.00 585,552
2 Nov 2026 Eric Venker President & CEO of Immunovant Open Market Disposition -200,000 $36.31 773,495
27 Oct 2026 Eric Venker President & CEO of Immunovant Automatic Disposition -200,000 $36.59 973,495
22 Oct 2026 James Momtazee Independent Director Sale to Issuer -77 $36.49 107,211
22 Oct 2026 James Momtazee Independent Director Other Acquisition +383 – 107,211
22 Oct 2026 Melissa Epperly Independent Director Sale to Issuer -116 $36.49 10,297
22 Oct 2026 Melissa Epperly Independent Director Other Acquisition +513 – 10,297
22 Oct 2026 Ilan Oren Independent Chairperson Other Acquisition +810 – 119,436

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 45,513,591 6.3% 6.1
15 Oct 2026 40,302,998 5.6% 7.9
30 Sep 2026 39,296,630 5.4% 4.4
15 Sep 2026 36,181,548 5.0% 4.1
31 Aug 2026 33,522,300 4.6% 3.8
14 Aug 2026 30,601,726 4.2% 5.0

Discussion

No comments yet — be the first to weigh in on ROIV.

Sign in to join the discussion.

Scroll to Top